Business Context and Reporting Period
This Form 6-K filing by Prana Biotechnology Limited (noted as Altery Therapeutics Ltd in metadata) covers the quarter ended March 31, 2004. The registrant is an Australian biotechnology entity admitted on the basis of commitments, reporting under ASX Appendix 4C rules.
Key Financial Metrics
All figures are in Australian Dollars (A$) in thousands.
| Metric | Current Quarter | Year-to-Date (9 Months) |
|---|---|---|
| Receipts from Customers | 755 | 1,734 |
| Net Operating Cash Flows | (1,876) | (4,412) |
| Net Investing Cash Flows | 0 | 0 |
| Net Financing Cash Flows | 0 | 4,714 |
| Net Increase (Decrease) in Cash | (1,876) | 302 |
| Cash at End of Period | 3,740 | 3,740 |
Operating Expenses (Current Quarter): Research and development costs were $2,059, staff costs were $291, and other working capital payments were $311. Advertising and marketing expenses were $35.
Material Changes
The filing does not provide comparative data for the prior year's quarter or year-to-date period, preventing a direct calculation of material changes versus the prior comparable period. However, the current quarter showed a net cash outflow of $1,876, while the year-to-date position improved by $302 due to financing activities.
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, or specific risk factors beyond the standard disclosure of cash flow activities. The entity reported no borrowings, no loan facilities used, and no credit standby arrangements utilized during the period. There were no acquisitions or disposals of business entities.
Investor Verification Checklist
- Verify the discrepancy between the metadata company name (Altery Therapeutics Ltd) and the filing registrant (Prana Biotechnology Limited).
- Confirm the sustainability of operations given the negative net operating cash flow of $1,876 for the quarter.
- Review the source of the $4,714 in proceeds from share issues recorded in the year-to-date financing section to understand capital structure changes.
- Assess the adequacy of the $3,740 cash balance against the reported quarterly burn rate.